港股医药板块本周领涨，关注港股通创新药ETF易方达（159316）、港股通医药ETF易方达（513200）投资价值

Core Viewpoint - The pharmaceutical industry is experiencing growth due to persistent human demand and unmet needs, alongside increased R&D investments by companies, marking the transition to an "innovation-driven" revenue era in China [1]. Index Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index rose by 3.3% this week, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 2.5%. Conversely, the CSI Innovative Drug Industry Index and the CSI Biotech Theme Index both declined by 0.2%, and the CSI 300 Healthcare Index fell by 0.6% [1][2]. - Year-to-date performance shows the CSI Hong Kong Stock Connect Healthcare Comprehensive Index up by 10.8%, while the CSI Innovative Drug Industry Index is down by 0.1% [7]. Valuation Metrics - The rolling P/E ratios for the indices are as follows: Hang Seng Hong Kong Stock Connect Innovative Drug Index at 55.6x, CSI Hong Kong Stock Connect Healthcare Comprehensive Index at 33.4x, CSI Innovative Drug Industry Index at 51.3x, CSI Biotech Theme Index at 54.1x, and CSI 300 Healthcare Index at 29.8x [2][6]. - As of July 2023, the valuation percentiles indicate that the Hang Seng Hong Kong Stock Connect Innovative Drug Index is at 53.0%, the CSI Hong Kong Stock Connect Healthcare Comprehensive Index at 75.2%, and the CSI Innovative Drug Industry Index at 61.5% [2]. Industry Trends - The pharmaceutical sector in China is becoming a significant player in global innovative drug development, with increasing enthusiasm for overseas licensing [1]. - The market is characterized by a focus on leading companies in innovative drug research, development, and production, with a concentration on healthcare industry stocks [3].